AR and prostate cancer: PCSCs usually have low or undetectable androgen receptor expression that can lead to the failure of androgen deprivation therapy (hormonal therapy), the standard primary treatment for advanced prostate cancer (Lee et al., 2013; Di Zazzo et al., 2016).